Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Head and Neck Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 84 articles:
HTML format



Single Articles


    August 2021
  1. HONG S, Zhang Y, Yu G, Peng P, et al
    Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    J Clin Oncol. 2021 Aug 11:JCO2100396. doi: 10.1200/JCO.21.00396.
    PubMed     Abstract available


  2. LI B, Chen H
    The Best Surgery Should Be Applied for Locally Advanced Esophageal Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101340. doi: 10.1200/JCO.21.01340.
    PubMed    


    June 2021
  3. HULSHOF MCCM, Geijsen ED, Rozema T, Oppedijk V, et al
    Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
    J Clin Oncol. 2021 Jun 8:JCO2003697. doi: 10.1200/JCO.20.03697.
    PubMed     Abstract available


  4. GOODMAN KA, Ou FS, Hall NC, Bekaii-Saab T, et al
    Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    J Clin Oncol. 2021 Jun 2:JCO2003611. doi: 10.1200/JCO.20.03611.
    PubMed     Abstract available


    May 2021
  5. LIU MA, Hsu WT, Johnstone C, Chang A, et al
    Interpreting the Clinical Utility of Early Interdisciplinary Supportive Care for Untreated Metastatic Esophageal Cancer.
    J Clin Oncol. 2021 May 7:JCO2100122. doi: 10.1200/JCO.21.00122.
    PubMed    


  6. YOKOYAMA K, Ishiki H
    Questions Regarding Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer.
    J Clin Oncol. 2021 May 5:JCO2100456. doi: 10.1200/JCO.21.00456.
    PubMed    


    April 2021
  7. EYCK BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, et al
    Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
    J Clin Oncol. 2021 Apr 23:JCO2003614. doi: 10.1200/JCO.20.03614.
    PubMed     Abstract available


  8. PEARSON AT, Vokes EE
    Is This the Dawn of Precision Oncology in Head and Neck Cancer?
    J Clin Oncol. 2021 Apr 20:JCO2100569. doi: 10.1200/JCO.21.00569.
    PubMed    


  9. HASEGAWA Y, Tsukahara K, Yoshimoto S, Miura K, et al
    Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.
    J Clin Oncol. 2021 Apr 20:JCO2003637. doi: 10.1200/JCO.20.03637.
    PubMed     Abstract available


  10. MINAMI H, Kiyota N, Omori T
    Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?
    J Clin Oncol. 2021 Apr 12:JCO2003262. doi: 10.1200/JCO.20.03262.
    PubMed    


    March 2021
  11. HO AL, Brana I, Haddad R, Bauman J, et al
    Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.
    J Clin Oncol. 2021 Mar 22:JCO2002903. doi: 10.1200/JCO.20.02903.
    PubMed     Abstract available


  12. CHAKRABARTI D, Akhtar N, Rajan S, Qayoom S, et al
    What Is the Acceptable Noninferiority Limit for Nodal Recurrences When Ascertaining Sentinel Lymph Node Biopsy as an Alternative to Neck Dissection for Early Oral and Oropharyngeal Cancers?
    J Clin Oncol. 2021 Mar 11:JCO2003439. doi: 10.1200/JCO.20.03439.
    PubMed    


    January 2021
  13. WANG FH, Wei XL, Feng J, Li Q, et al
    Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    J Clin Oncol. 2021 Jan 25:JCO2002712. doi: 10.1200/JCO.20.02712.
    PubMed     Abstract available


  14. CHEUNG LC, Ramadas K, Muwonge R, Katki HA, et al
    Risk-Based Selection of Individuals for Oral Cancer Screening.
    J Clin Oncol. 2021 Jan 15:JCO2002855. doi: 10.1200/JCO.20.02855.
    PubMed     Abstract available


  15. LU Z, Fang Y, Liu C, Zhang X, et al
    Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol. 2021 Jan 8:JCO2001254. doi: 10.1200/JCO.20.01254.
    PubMed     Abstract available


  16. NOEL CW, Sutradhar R, Zhao H, Delibasic V, et al
    Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer: A Longitudinal Population-Based Study.
    J Clin Oncol. 2021 Jan 6:JCO2001845. doi: 10.1200/JCO.20.01845.
    PubMed     Abstract available


  17. CHEN YP, Ismaila N, Chua MLK, Colevas AD, et al
    Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.
    J Clin Oncol. 2021 Jan 6:JCO2003237. doi: 10.1200/JCO.20.03237.
    PubMed     Abstract available


  18. GEBRE-MEDHIN M, Brun E, Engstrom P, Haugen Cange H, et al
    ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.
    J Clin Oncol. 2021;39:38-47.
    PubMed     Abstract available


  19. SEIWERT TY, Kiess AP
    Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1.
    J Clin Oncol. 2021;39:1-3.
    PubMed    


  20. WIJNHOVEN BPL, Lagarde SM
    Minimally Invasive Esophagectomy: Time to Reflect on Contemporary Outcomes.
    J Clin Oncol. 2021;39:90-91.
    PubMed    


  21. NUYTENS F, Voron T, Piessen G
    Hybrid Minimally Invasive Esophagectomy to the Rescue: A Valid Alternative for Phased Dissemination of TMIE?
    J Clin Oncol. 2021;39:91-92.
    PubMed    


    December 2020
  22. JHAWAR SR, Bonomi M, Harari PM
    Treating Advanced Head and Neck Cancer When Cisplatin Is Not an Option.
    J Clin Oncol. 2020 Dec 4:JCO2002720. doi: 10.1200/JCO.20.02720.
    PubMed     Abstract available


  23. LAI SY, Ferris RL
    Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer.
    J Clin Oncol. 2020;38:3983-3986.
    PubMed    


  24. GARREL R, Poissonnet G, Moya Plana A, Fakhry N, et al
    Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2020;38:4010-4018.
    PubMed     Abstract available


    October 2020
  25. KOJIMA T, Shah MA, Muro K, Francois E, et al
    Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
    J Clin Oncol. 2020 Oct 7:JCO2001888. doi: 10.1200/JCO.20.01888.
    PubMed     Abstract available


    August 2020
  26. MCBRIDE S, Sherman E, Tsai CJ, Baxi S, et al
    Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.
    J Clin Oncol. 2020 Aug 21:JCO2000290. doi: 10.1200/JCO.20.00290.
    PubMed     Abstract available


  27. KREISSL MC, Bastholt L, Elisei R, Haddad R, et al
    Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
    J Clin Oncol. 2020;38:2773-2781.
    PubMed     Abstract available


  28. SHAH MA, Kennedy EB, Catenacci DV, Deighton DC, et al
    Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline.
    J Clin Oncol. 2020;38:2677-2694.
    PubMed     Abstract available


  29. MAGHAMI E, Ismaila N, Alvarez A, Chernock R, et al
    Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline.
    J Clin Oncol. 2020;38:2570-2596.
    PubMed     Abstract available


    July 2020
  30. SIMONE CB 2ND
    First Randomized Trial Supporting the Use of Proton Over Photon Chemoradiotherapy in Esophageal Cancer.
    J Clin Oncol. 2020 Jul 24:JCO2001405. doi: 10.1200/JCO.20.01405.
    PubMed    


  31. CATENACCI DVT, Rasco D, Lee J, Rha SY, et al
    Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
    J Clin Oncol. 2020;38:2418-2426.
    PubMed     Abstract available


    June 2020
  32. LIM AM, Solomon BJ
    Immunotherapy for Anaplastic Thyroid Carcinoma.
    J Clin Oncol. 2020 Jun 18:JCO2001437. doi: 10.1200/JCO.20.01437.
    PubMed    


  33. MAKIYAMA A, Sukawa Y, Kashiwada T, Kawada J, et al
    Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    J Clin Oncol. 2020;38:1919-1927.
    PubMed     Abstract available


  34. MEHANNA H, Rischin D, Wong SJ, Gregoire V, et al
    De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies.
    J Clin Oncol. 2020 Jun 4:JCO2000056. doi: 10.1200/JCO.20.00056.
    PubMed     Abstract available


  35. POWELL SF, Gold KA, Gitau MM, Sumey CJ, et al
    Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
    J Clin Oncol. 2020 Jun 1:JCO1903156. doi: 10.1200/JCO.19.03156.
    PubMed     Abstract available


  36. KANN BH, Payabvash S, Aneja S
    Reply to A.B. Simon et al.
    J Clin Oncol. 2020;38:1869-1870.
    PubMed    


  37. SIMON AB, Vitzthum LK, Mell LK
    Challenge of Directly Comparing Imaging-Based Diagnoses Made by Machine Learning Algorithms With Those Made by Human Clinicians.
    J Clin Oncol. 2020;38:1868-1869.
    PubMed    


    May 2020
  38. CAPDEVILA J, Wirth LJ, Ernst T, Ponce Aix S, et al
    PD-1 Blockade in Anaplastic Thyroid Carcinoma.
    J Clin Oncol. 2020 May 4:JCO1902727. doi: 10.1200/JCO.19.02727.
    PubMed     Abstract available


    April 2020
  39. CHERA BS, Kumar S, Shen C, Amdur R, et al
    Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
    J Clin Oncol. 2020;38:1050-1058.
    PubMed     Abstract available


    March 2020
  40. LIN SH, Hobbs BP, Verma V, Tidwell RS, et al
    Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.
    J Clin Oncol. 2020 Mar 11:JCO1902503. doi: 10.1200/JCO.19.02503.
    PubMed     Abstract available


  41. O'SULLIVAN B, Huang SH, de Almeida JR, Hope A, et al
    Alpha Test of Intelligent Machine Learning in Staging Head and Neck Cancer.
    J Clin Oncol. 2020 Mar 2:JCO1903309. doi: 10.1200/JCO.19.03309.
    PubMed    


    February 2020
  42. IQBAL S, McDonough S, Lenz HJ, Ilson D, et al
    Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201.
    J Clin Oncol. 2020;38:472-479.
    PubMed     Abstract available


  43. STROES CI, Schokker S, Creemers A, Molenaar RJ, et al
    Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
    J Clin Oncol. 2020;38:462-471.
    PubMed     Abstract available


    December 2019
  44. KANN BH, Hicks DF, Payabvash S, Mahajan A, et al
    Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma.
    J Clin Oncol. 2019 Dec 9:JCO1902031. doi: 10.1200/JCO.19.02031.
    PubMed     Abstract available


    October 2019
  45. ARGIRIS A, Li S, Savvides P, Ohr JP, et al
    Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
    J Clin Oncol. 2019 Oct 16:JCO1900555. doi: 10.1200/JCO.19.00555.
    PubMed     Abstract available


  46. ANDERSON CM, Lee CM, Saunders DP, Curtis A, et al
    Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
    J Clin Oncol. 2019 Oct 16:JCO1901507. doi: 10.1200/JCO.19.01507.
    PubMed     Abstract available


    September 2019
  47. RODRIGUEZ-GALINDO C, Krailo MD, Krasin MJ, Huang L, et al
    Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
    J Clin Oncol. 2019 Sep 25:JCO1901276. doi: 10.1200/JCO.19.01276.
    PubMed     Abstract available


  48. PATIL VM, Noronha V, Joshi A, Dhumal S, et al
    Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
    J Clin Oncol. 2019 Sep 20:JCO1901076. doi: 10.1200/JCO.19.01076.
    PubMed     Abstract available


  49. JELINEK MJ, Vokes EE
    Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
    J Clin Oncol. 2019 Sep 4:JCO1901981. doi: 10.1200/JCO.19.01981.
    PubMed    


    August 2019
  50. ROGERS JE, Ajani JA
    Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy.
    J Clin Oncol. 2019 Aug 29:JCO1901247. doi: 10.1200/JCO.19.01247.
    PubMed    


    June 2019
  51. HARARI PM
    Open the Gates for Treatment De-Intensification in Head and Neck Cancer.
    J Clin Oncol. 2019 Jun 13:JCO1901296. doi: 10.1200/JCO.19.01296.
    PubMed    


    May 2019
  52. FERRIS RL, Cramer JD, Branstetter Iv BF
    Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma.
    J Clin Oncol. 2019 May 31:JCO1900544. doi: 10.1200/JCO.19.00544.
    PubMed    


    February 2019
  53. AMIT M, Abdelmeguid AS, Watcherporn T, Takahashi H, et al
    Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma.
    J Clin Oncol. 2019;37:504-512.
    PubMed     Abstract available


  54. LOWE VJ, Duan F, Subramaniam RM, Sicks JD, et al
    Multicenter Trial of [(18)F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685.
    J Clin Oncol. 2019 Feb 15:JCO1801182. doi: 10.1200/JCO.18.01182.
    PubMed     Abstract available


    January 2019
  55. TAKAHASHI H, Tada Y, Saotome T, Akazawa K, et al
    Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
    J Clin Oncol. 2019;37:125-134.
    PubMed     Abstract available


    November 2018
  56. JIANG J, Li Y, Shen Q, Rong X, et al
    Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2018 Nov 20:JCO1800896. doi: 10.1200/JCO.18.00896.
    PubMed     Abstract available


    September 2018
  57. FAKHRY C, Lacchetti C, Rooper LM, Jordan RC, et al
    Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline.
    J Clin Oncol. 2018 Sep 6:JCO1800684. doi: 10.1200/JCO.18.00684.
    PubMed     Abstract available


    August 2018
  58. JANJIGIAN YY, Bendell J, Calvo E, Kim JW, et al
    CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
    J Clin Oncol. 2018 Aug 15:JCO2017766212. doi: 10.1200/JCO.2017.76.6212.
    PubMed     Abstract available


    July 2018
  59. GEOFFROIS L, Martin L, De Raucourt D, Sun XS, et al
    Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.
    J Clin Oncol. 2018 Jul 17:JCO2017762591. doi: 10.1200/JCO.2017.76.2591.
    PubMed     Abstract available


    June 2018
  60. TAO Y, Auperin A, Sire C, Martin L, et al
    Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.
    J Clin Oncol. 2018 Jun 7:JCO2017762518. doi: 10.1200/JCO.2017.76.2518.
    PubMed     Abstract available


    May 2018
  61. FISHER R
    Questionable Relevance of Leukemia Risk After Radioiodine Ablation of Thyroid Cancer.
    J Clin Oncol. 2018 May 3:JCO2018781534. doi: 10.1200/JCO.2018.78.1534.
    PubMed    


  62. PICCARDO A, Puntoni M, Verburg FA, Luster M, et al
    Power of Absolute Values to Avoid Data Misinterpretations: The Case of Radioiodine-Induced Leukemia and Myelodysplasia.
    J Clin Oncol. 2018 May 3:JCO2018777318. doi: 10.1200/JCO.2018.77.7318.
    PubMed    


    March 2018
  63. MA BBY, Lim WT, Goh BC, Hui EP, et al
    Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
    J Clin Oncol. 2018 Mar 27:JCO2017770388. doi: 10.1200/JCO.2017.77.0388.
    PubMed     Abstract available


  64. BHATIA AK, Burtness BA, Decker RH
    Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    J Clin Oncol. 2018 Mar 16:JCO2018777987. doi: 10.1200/JCO.2018.77.7987.
    PubMed    


  65. PORCEDDU SV, Bressel M, Poulsen MG, Stoneley A, et al
    Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.
    J Clin Oncol. 2018 Mar 14:JCO2017770941. doi: 10.1200/JCO.2017.77.0941.
    PubMed     Abstract available


    February 2018
  66. THAI AA, Rischin D
    High-Dose Cisplatin for Head and Neck Cancer Lives On.
    J Clin Oncol. 2018 Feb 2:JCO2017768614. doi: 10.1200/JCO.2017.76.8614.
    PubMed    


    December 2017
  67. QUON H, Vapiwala N, Forastiere A, Kennedy EB, et al
    Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
    J Clin Oncol. 2017;35:4078-4090.
    PubMed     Abstract available


  68. FAKHRY C, Zhang Q, Nguyen-Tan PF, Rosenthal DI, et al
    Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.
    J Clin Oncol. 2017;35:4057-4065.
    PubMed     Abstract available


  69. NORONHA V, Joshi A, Patil VM, Agarwal J, et al
    Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
    J Clin Oncol. 2017 Dec 8:JCO2017749457. doi: 10.1200/JCO.2017.74.9457.
    PubMed     Abstract available


    November 2017
  70. FORASTIERE AA, Ismaila N, Lewin JS, Nathan CA, et al
    Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017 Nov 27:JCO2017757385. doi: 10.1200/JCO.2017.75.7385.
    PubMed     Abstract available


  71. HO AS, Kim S, Tighiouart M, Gudino C, et al
    Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer.
    J Clin Oncol. 2017;35:3601-3609.
    PubMed     Abstract available


    October 2017
  72. VAN DEN WYNGAERT T, Helsen N, Carp L, Hakim S, et al
    Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study.
    J Clin Oncol. 2017;35:3458-3464.
    PubMed     Abstract available


  73. CABANILLAS ME, de Souza JA, Geyer S, Wirth LJ, et al
    Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    J Clin Oncol. 2017;35:3315-3321.
    PubMed     Abstract available


    August 2017
  74. HSU C, Lee SH, Ejadi S, Even C, et al
    Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    J Clin Oncol. 2017 Aug 24:JCO2017733675. doi: 10.1200/JCO.2017.73.3675.
    PubMed     Abstract available


  75. BROSE MS, Worden FP, Newbold KL, Guo M, et al
    Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    J Clin Oncol. 2017;35:2692-2699.
    PubMed     Abstract available


  76. EBISCH RMF, Rutten DWE, IntHout J, Melchers WJG, et al
    Long-Lasting Increased Risk of Human Papillomavirus-Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study.
    J Clin Oncol. 2017;35:2542-2550.
    PubMed     Abstract available


    May 2017
  77. PETTY RD, Dahle-Smith A, Stevenson DAJ, Osborne A, et al
    Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
    J Clin Oncol. 2017 May 24:JCO2016703934. doi: 10.1200/JCO.2016.70.3934.
    PubMed     Abstract available


  78. TRIFILETTI DM, Smith A, Mitra N, Grover S, et al
    Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.
    J Clin Oncol. 2017;35:1550-1560.
    PubMed     Abstract available


  79. SZTURZ P, Seiwert TY, Vermorken JB
    How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
    J Clin Oncol. 2017 May 4:JCO2016718072. doi: 10.1200/JCO.2016.71.8072.
    PubMed    


    March 2017
  80. BAUML J, Seiwert TY, Pfister DG, Worden F, et al
    Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
    J Clin Oncol. 2017 Mar 22:JCO2016701524. doi: 10.1200/JCO.2016.70.1524.
    PubMed     Abstract available


    February 2017
  81. MARUR S, Li S, Cmelak AJ, Gillison ML, et al
    E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
    J Clin Oncol. 2017;35:490-497.
    PubMed     Abstract available


  82. BARTLEY AN, Washington MK, Colasacco C, Ventura CB, et al
    HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
    J Clin Oncol. 2017;35:446-464.
    PubMed     Abstract available


    January 2017
  83. FERRAROTTO R, Mitani Y, Diao L, Guijarro I, et al
    Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    J Clin Oncol. 2017;35:352-360.
    PubMed     Abstract available


    December 2016
  84. JANSEN F, Krebber AM, Coupe VM, Cuijpers P, et al
    Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer.
    J Clin Oncol. 2016 Dec 5:JCO2016688739.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: